<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome - Allegretti, AS - 2017 | Cochrane Library</title> <meta content="Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome - Allegretti, AS - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005162.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome - Allegretti, AS - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005162.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005162.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome" name="citation_title"/> <meta content="Andrew S Allegretti" name="citation_author"/> <meta content="Massachusetts General Hospital" name="citation_author_institution"/> <meta content="Mads Israelsen" name="citation_author"/> <meta content="Odense University Hospital" name="citation_author_institution"/> <meta content="Aleksander Krag" name="citation_author"/> <meta content="Odense University Hospital" name="citation_author_institution"/> <meta content="Manol Jovani" name="citation_author"/> <meta content="Massachusetts General Hospital and Harvard Medical School" name="citation_author_institution"/> <meta content="Alison H Goldin" name="citation_author"/> <meta content="Brigham and Women's Hospital" name="citation_author_institution"/> <meta content="Allison R Schulman" name="citation_author"/> <meta content="Brigham and Women's Hospital" name="citation_author_institution"/> <meta content="Rachel W Winter" name="citation_author"/> <meta content="Brigham and Women's Hospital" name="citation_author_institution"/> <meta content="Lise Lotte Gluud" name="citation_author"/> <meta content="Copenhagen University Hospital Hvidovre" name="citation_author_institution"/> <meta content="liselottegluud@yahoo.dk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD005162.pub4" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/06/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005162.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005162.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005162.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Abdominal Pain [chemically induced]; Albumins [therapeutic use]; Diarrhea [chemically induced]; Hepatorenal Syndrome [classification, *drug therapy, mortality]; Lypressin [adverse effects, *analogs &amp; derivatives, therapeutic use]; Randomized Controlled Trials as Topic; Terlipressin; Vasoconstrictor Agents [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005162.pub4&amp;doi=10.1002/14651858.CD005162.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="SVRJ5zHF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005162\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005162\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005162.pub4",title:"Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome",firstPublishedDate:"Jun 14, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato‐Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=SVRJ5zHF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005162.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005162.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005162.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005162.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005162.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005162.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005162.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005162.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005162.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005162.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3153 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005162.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#CD005162-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#CD005162-sec-0096"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#CD005162-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#CD005162-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#CD005162-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#CD005162-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#CD005162-sec-0071"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#CD005162-sec-0090"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/appendices#CD005162-sec-0101"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/table_n/CD005162StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/table_n/CD005162StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/information#CD005162-cr-0002">Andrew S Allegretti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/information#CD005162-cr-0003">Mads Israelsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/information#CD005162-cr-0004">Aleksander Krag</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/information#CD005162-cr-0005">Manol Jovani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/information#CD005162-cr-0006">Alison H Goldin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/information#CD005162-cr-0007">Allison R Schulman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/information#CD005162-cr-0008">Rachel W Winter</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005162.pub4/information#CD005162-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Lise Lotte Gluud</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/information/en#CD005162-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 June 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005162.pub4">https://doi.org/10.1002/14651858.CD005162.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005162-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005162-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005162-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005162-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005162-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005162-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005162-abs-0001" lang="en"> <section id="CD005162-sec-0001"> <h3 class="title" id="CD005162-sec-0001">Background</h3> <p>Hepatorenal syndrome is a potentially reversible renal failure associated with severe liver disease. The disease is relatively common among people with decompensated cirrhosis. Terlipressin is a drug that increases the blood flow to the kidneys by constricting blood vessels. The previous version of this systematic review found a potential beneficial effect of terlipressin on mortality and renal function in people with cirrhosis and hepatorenal syndrome. </p> </section> <section id="CD005162-sec-0002"> <h3 class="title" id="CD005162-sec-0002">Objectives</h3> <p>To assess the beneficial and harmful effects of terlipressin versus placebo/no intervention for people with cirrhosis and hepatorenal syndrome. </p> </section> <section id="CD005162-sec-0003"> <h3 class="title" id="CD005162-sec-0003">Search methods</h3> <p>We identified eligible trials through searches of the Cochrane Hepato‐Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE, Embase, and Science Citation Index Expanded, and manual searches until 21 November 2016. </p> </section> <section id="CD005162-sec-0004"> <h3 class="title" id="CD005162-sec-0004">Selection criteria</h3> <p>Randomised clinical trials (RCTs) involving participants with cirrhosis and type 1 or type 2 hepatorenal syndrome allocated to terlipressin versus placebo or no intervention. We allowed co‐administration with albumin administered to both comparison groups. </p> </section> <section id="CD005162-sec-0005"> <h3 class="title" id="CD005162-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data from trial reports and undertook correspondence with the authors. Primary outcomes were mortality, hepatorenal syndrome, and serious adverse events. We conducted sensitivity analyses of RCTs in which participants received albumin, subgroup analyses of participants with type 1 or type 2 hepatorenal syndrome, and Trial Sequential Analyses to control random errors. We reported random‐effects meta‐analyses with risk ratios (RR) and 95% confidence intervals (CI). We assessed the risk of bias based on the Cochrane Hepato‐Biliary Group domains. We graded the quality of the evidence using GRADE. </p> </section> <section id="CD005162-sec-0006"> <h3 class="title" id="CD005162-sec-0006">Main results</h3> <p>We included nine RCTs with a total of 534 participants with cirrhosis and ascites. One RCT had a low risk of bias for mortality and a high risk of bias for the remaining outcomes. All included trials had a high risk of bias for non‐mortality outcomes. In total, 473 participants had type 1 hepatorenal syndrome. Seven RCTs specifically evaluated terlipressin and albumin. Terlipressin was associated with a beneficial effect on mortality when including all RCTs (RR 0.85, 95% CI 0.73 to 0.98; 534 participants; number needed to treat for an additional beneficial outcome (NNTB) 10.3 people; low‐quality evidence). Trial Sequential Analysis including all RCTs also found a beneficial effect of terlipressin. Additional analyses showed a beneficial effect of terlipressin and albumin on reversal of hepatorenal syndrome (RR 0.63, 95% CI 0.48 to 0.82; 510 participants; 8 RCTs; NNTB 4 people; low‐quality evidence). Terlipressin increased the risk of serious cardiovascular adverse events (RR 7.26, 95% CI 1.70 to 31.05; 234 participants; 4 RCTs), but it had no effect on the risk of serious adverse events when analysed as a composite outcome (RR 0.91, 95% CI 0.68 to 1.21; 534 participants; 9 RCTs; number needed to treat for an additional harmful outcome 24.5 people; low‐quality evidence). Non‐serious adverse events were mainly gastrointestinal, including diarrhoea (RR 5.76, 95% CI 2.19 to 15.15; 240 participants; low‐quality evidence) and abdominal pain (RR 1.54, 95% CI 0.97 to 2.43; 294 participants; low‐quality evidence). </p> <p>We identified one ongoing trial on terlipressin versus placebo in participants with cirrhosis, ascites, and hepatorenal syndrome type 1. </p> <p>Three RCTs reported funding from a pharmaceutical company. The remaining trials did not report funding or did not receive funding from pharmaceutical companies. </p> </section> <section id="CD005162-sec-0007"> <h3 class="title" id="CD005162-sec-0007">Authors' conclusions</h3> <p>This review suggests that terlipressin may be associated with beneficial effects on mortality and renal function in people with cirrhosis and type 1 hepatorenal syndrome, but it is also associated with serious adverse effects. We downgraded the strength of the evidence due to methodological issues including bias control, clinical heterogeneity, and imprecision. Consequently, additional evidence is needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005162-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005162-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005162-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005162-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005162-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005162-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005162-abs-0003" lang="en"> <h3>Terlipressin versus placebo/no intervention for people with cirrhosis and hepatorenal syndrome </h3> <p><b>Background</b> </p> <p>Cirrhosis is a chronic disorder of the liver where scar tissue replaces the normal liver. People with cirrhosis can develop a kidney disease known as hepatorenal syndrome. The disease may develop when the blood flow to the kidneys becomes insufficient. Increasing the blood flow to the kidneys may therefore benefit people with hepatorenal syndrome. There are two types of hepatorenal syndrome: type 1 occurs rapidly, and type 2 has a slower onset. Terlipressin is a drug that increases the blood flow to the kidneys by constricting blood vessels. The drug may therefore help people with cirrhosis and hepatorenal syndrome. </p> <p><b>Review question</b> </p> <p>Is terlipressin better than inactive placebo/no treatment for people with hepatorenal syndrome? </p> <p><b>Search date</b> </p> <p>November 2016.</p> <p><b>Study characteristics</b> </p> <p>The review includes nine randomised clinical trials (RCTs) and a total of 534 participants. The trials originated from six countries. Seven trials included only participants with type 1 hepatorenal syndrome. Two trials included a total of 96 participants with type 1 or type 2 hepatorenal syndrome. </p> <p><b>Study funding sources</b> </p> <p>Three RCTs reported funding from a pharmaceutical company. The remaining trials did not report funding or did not receive funding from pharmaceutical companies. </p> <p><b>Key results</b> </p> <p>People who received terlipressin had a lower risk of dying than people who received inactive placebo or no treatment. Terlipressin was also associated with a beneficial effect on renal function. Terlipressin increased the risk of serious circulation and heart problems (so‐called cardiovascular events). Other adverse events included diarrhoea and abdominal pain. </p> <p>The analyses mainly included people with type 1 hepatorenal syndrome. No beneficial or harmful effects of terlipressin were found when analysing participants with type 2 hepatorenal syndrome (possibly due to the small number of participants). </p> <p><b>Quality of the evidence</b> </p> <p>We considered the evidence to be of low quality.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005162-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005162-sec-0096"></div> <h3 class="title" id="CD005162-sec-0097">Implications for practice</h3> <section id="CD005162-sec-0097"> <p>This review includes RCTs evaluating people with cirrhosis and hepatorenal syndrome. The main body of evidence evaluated terlipressin and albumin for participants with type 1 hepatorenal syndrome. The number of RCTs evaluating terlipressin without albumin and the number of participants with type 2 hepatorenal syndrome were small. The analyses suggest a potential beneficial effect of terlipressin on mortality and hepatorenal syndrome, but also an increased risk of serious cardiovascular adverse events and gastrointestinal events such as diarrhoea. </p> </section> <h3 class="title" id="CD005162-sec-0098">Implications for research</h3> <section id="CD005162-sec-0098"> <p>We used the EPICOT format in the definition of implications for research (<a href="./references#CD005162-bbs2-0024" title="BrownP , BrunnhuberK , ChalkidouK , ChalmersI , ClarkeM , FentonM , et al. How to formulate research recommendations. BMJ (Clinical Research Ed.)2006;333:804‐6. ">Brown 2006</a>): </p> <p><b>E</b>vidence (what is the current state of the evidence?): this review includes seven RCTs and found low‐quality evidence that combined terlipressin and albumin has both beneficial and harmful effects in the management of people with type 1 hepatorenal syndrome. Additional research is needed to further evaluate the effect of the intervention in type 2 hepatorenal syndrome. </p> <p><b>P</b>articipants (what is the population of interest?): the largest body of evidence evaluated people with cirrhosis and type 1 hepatorenal syndrome. Future RCTs should consider evaluating participants with hepatorenal syndrome defined using current guidelines. </p> <p><b>I</b>nterventions (what are the interventions of interest?): the interventions assessed included terlipressin in doses ranging from 1 mg twice a day up to 2 mg six times a day for a median duration of 15 days (range 2 to 19 days). </p> <p><b>C</b>omparisons (what are the comparisons of interest?): placebo or no intervention. </p> <p><b>O</b>utcomes (what are the outcomes of interest?): RCTs should include an assessment of mortality, hepatorenal syndrome, and adverse events. Additional evidence evaluating the effect on health‐related quality of life is also needed. </p> <p><b>T</b>ime stamp (date of literature search): November 2016. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005162-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005162-sec-0029"></div> <div class="table" id="CD005162-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Terlipressin versus placebo or no intervention for hepatorenal syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Terlipressin versus placebo or no intervention for hepatorenal syndrome. Administration of albumin allowed if administered to both the intervention and comparison group</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with hepatorenal syndrome<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> terlipressin alone or terlipressin plus albumin </p> <p><b>Comparison:</b> placebo or no intervention or albumin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with terlipressin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.85 (0.73 to 0.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>534<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Downgraded because of i) clinical heterogeneity and ii) the results of the Trial Sequential Analysis </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>688 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>536 per 1000<br/> (433 to 660) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>488 per 1000<br/> (394 to 600) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Hepatorenal syndrome</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.63 (0.48 to 0.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>510<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Downgraded because of i) clinical heterogeneity and ii) all trials are judged as 'high risk of bias'. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>879 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>510 per 1000<br/> (431 to 606) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>875 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>507 per 1000<br/> (429 to 604) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91 (0.68 to 1.21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>534 (9 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Downgraded because of i) clinical heterogeneity and ii) all RCTs are judged as high risk of bias. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>212 per 1000<br/> (131 to 344) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious cardiovascular adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 7.26 (1.70 to 31.05)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>234<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Downgraded because of i) clinical heterogeneity and ii) all RCTs are judged as high risk of bias </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Abdominal pain</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.54 (0.97 to 2.43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>294 (4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Downgraded because of i) clinical heterogeneity and ii) all RCTs are judged as high risk of bias </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>149 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>229 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diarrhoea</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.76 (2.19 to 15.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>240 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Downgraded because of i) clinical heterogeneity and ii) all RCTs are judged as high risk of bias </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Not confirmed in analyses of randomised clinical trials (RCTs) with a low risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005162-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005162-sec-0030"></div> <section id="CD005162-sec-0031"> <h3 class="title" id="CD005162-sec-0031">Description of the condition</h3> <p>Hepatorenal syndrome is a potentially reversible renal failure associated with severe liver disease (<a href="./references#CD005162-bbs2-0023" title="ArroyoV , GinesP , GerbesAL , DudleyFJ , GentiliniP , LaffiG , et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology (Baltimore, Md.)1996;23:164‐76. ">Arroyo 1996</a>). The disease is relatively common among people with decompensated cirrhosis. Over 20% of people with decompensated cirrhosis become hospitalised with renal failure, among whom up to 20% have hepatorenal syndrome (<a href="./references#CD005162-bbs2-0030" title="GinesA , EscorsellA , GinesP , SaloJ , JimenezW , IngladaL , et al. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology1993;105:229‐36. [MEDLINE: PMID: 8514039] ">Gines 1993</a>; <a href="./references#CD005162-bbs2-0029" title="Garcia‐TsaoG , ParikhCR , ViolaA . Acute kidney injury and cirrhosis. Hepatology (Baltimore, Md.)2008;48:2064‐77. ">Garcia‐Tsao 2008</a>; <a href="./references#CD005162-bbs2-0038" title="IsraelsenME , GluudLL , KragA . Acute kidney injury and hepatorenal syndrome in cirrhosis. Journal of Gastroenterology and Hepatology2015;30:236‐43. ">Israelsen 2015b</a>). The diagnosis includes cirrhosis and ascites plus impaired renal function after exclusion of parenchymal renal disease and factors that may precipitate renal dysfunction in cirrhosis (<a href="./references#CD005162-bbs2-0047" title="SalernoF , GerbesA , GinèsP , WongF , ArroyoV . Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut2007;56:1310‐8. ">Salerno 2007</a>). Hepatorenal syndrome is divided into two types, with type 1 having the most rapid course of development. Without treatment, type 1 has a median survival of about two weeks and type 2 a median survival of about six months (<a href="./references#CD005162-bbs2-0023" title="ArroyoV , GinesP , GerbesAL , DudleyFJ , GentiliniP , LaffiG , et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology (Baltimore, Md.)1996;23:164‐76. ">Arroyo 1996</a>; <a href="./references#CD005162-bbs2-0031" title="GinesP , GuevaraM , ArroyoV , RodesJ . Hepatorenal syndrome. Lancet2003;362:1819‐27. ">Gines 2003</a>; <a href="./references#CD005162-bbs2-0047" title="SalernoF , GerbesA , GinèsP , WongF , ArroyoV . Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut2007;56:1310‐8. ">Salerno 2007</a>). </p> </section> <section id="CD005162-sec-0032"> <h3 class="title" id="CD005162-sec-0032">Description of the intervention</h3> <p>The development of hepatorenal syndrome is associated with the circulatory changes seen in cirrhosis of the liver subsequent to portal hypertension and vasodilation of the splanchnic vasculature (<a href="./references#CD005162-bbs2-0025" title="CardenasA , ArroyoV . Hepatorenal syndrome. Annals of Hepatology2003;2:23‐9. ">Cardenas 2003</a>). This vasodilation results in effective underfilling of the renal arteries and activation of the renin‐angiotensin‐aldosterone, the arginine‐vasopressin, and the sympathetic nervous systems (<a href="./references#CD005162-bbs2-0042" title="PasqualettiP , FestucciaV , CollaccianiA , AcitelliP , CasaleR . Circadian rhythm of arginine vasopressin in hepatorenal syndrome. Nephron1998;78:33‐7. ">Pasqualetti 1998</a>; <a href="./references#CD005162-bbs2-0040" title="MollerS , HenriksenJH . Review article: pathogenesis and pathophysiology of hepatorenal syndrome‐‐is there scope for prevention?. Alimentary Pharmacology &amp; Therapeutics2004;20:31‐41. ">Moller 2004</a>; <a href="./references#CD005162-bbs2-0045" title="Ruiz‐del‐ArbolL , MonescilloA , ArocenaC , ValerP , GinesP , MoreiraV , et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology (Baltimore, Md.)2005;42:439‐47. ">Ruiz del Arbol 2005</a>). Activation of these systems may in turn lead to severe vasoconstriction of the renal arteries and hepatorenal syndrome (<a href="./references#CD005162-bbs2-0025" title="CardenasA , ArroyoV . Hepatorenal syndrome. Annals of Hepatology2003;2:23‐9. ">Cardenas 2003</a>). Current treatments focus on improvement of renal blood flow and effective arterial circulation. This is done with volume expanders (such as intravenous albumin) or with vasoactive drugs that preferentially constrict the splanchnic circulation, such as terlipressin. </p> </section> <section id="CD005162-sec-0033"> <h3 class="title" id="CD005162-sec-0033">How the intervention might work</h3> <p>Vasoactive drugs that increase the splanchnic arterial tone may reverse hepatorenal syndrome. Vasopressin is a potential candidate, but may lead to severe ischaemia of the mesenteric mucosa, skin, and myocardium (<a href="./references#CD005162-bbs2-0041" title="ObritschMD , BestulDJ , JungR , FishDN , MacLarenR . The role of vasopressin in vasodilatory septic shock. Pharmacotherapy2004;24:1050‐3. ">Obritsch 2004</a>). A controlled trial found that the vasopressin analogue terlipressin may be a safer alternative (<a href="./references#CD005162-bbs2-0028" title="FreemanJG , CobdenI , LishmanAH , RecordCO . Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices. Lancet1982;2:66‐8. ">Freeman 1982</a>). Terlipressin is administered intravenously either by bolus or continuous infusion. It is commonly titrated based on desired change in mean arterial pressure. It has both systemic and splanchnic constrictive effects, so adverse events include sequelae of vasoconstriction, such as mild gastrointestinal symptoms (e.g. diarrhoea and abdominal pain) or more severe evidence of ischaemia. </p> </section> <section id="CD005162-sec-0034"> <h3 class="title" id="CD005162-sec-0034">Why it is important to do this review</h3> <p>Two initial randomised clinical trials (RCTs) evaluated terlipressin for participants with hepatorenal syndrome; however, they were small and had short‐term follow‐up (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>). Three subsequent larger RCTs found no convincing effects on mortality (<a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>). Three meta‐analyses of RCTs and observational studies reached equivocal findings (<a href="./references#CD005162-bbs2-0027" title="FabriziF , DixitV , MessaP , MartinP . Terlipressin for hepatorenal syndrome: a meta‐analysis of randomized trials. International Journal of Artificial Organs2009;32:133‐40. ">Fabrizi 2009</a>; <a href="./references#CD005162-bbs2-0026" title="DobreM , DemirjianS , SehgalAR , NavaneethanSD . Terlipressin in hepatorenal syndrome: a systematic review and meta‐analysis. International Urology and Nephrology2011;43(1):175‐84. ">Dobre 2010</a>; <a href="./references#CD005162-bbs2-0046" title="SagiSV , MittalS , KasturiKS , SoodGK . Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta‐analysis of randomized controlled trials. Journal of Gastroenterology and Hepatology2010;25:880‐5. ">Sagi 2010</a>). In the previous version of this systematic review, we found a potential beneficial effect of terlipressin on mortality and reversal of hepatorenal syndrome (<a href="./references#CD005162-bbs2-0053" title="GluudLL , KjaerMS , ChristensenE . Terlipressin for hepatorenal syndrome. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD005162] ">Gluud 2006</a>), but we also identified potential methodological concerns. We updated the review to include the currently available evidence. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005162-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005162-sec-0035"></div> <p>To assess the beneficial and harmful effects of terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005162-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005162-sec-0036"></div> <section id="CD005162-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005162-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included RCTs irrespective of blinding, publication status, or language. We included the first period from cross‐over RCTs. In addition, we planned to include quasi‐randomised studies and observational studies in our assessment of serious adverse events (<a href="./references#CD005162-bbs2-0034" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), although this is a known limitation making us focus more on benefits than on harms (<a href="./references#CD005162-bbs2-0032" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2017, Issue 1. Art. No.: LIVER. ">Gluud 2017</a>). </p> </section> <section id="CD005162-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included people with cirrhosis and type 1 or type 2 hepatorenal syndrome (defined as an increase in creatinine in people with ascites and no other causes of renal disease). </p> </section> <section id="CD005162-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included RCTs comparing terlipressin (any dose or duration) versus placebo or no intervention. We allowed co‐administration of albumin given to both comparison groups. </p> </section> <section id="CD005162-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>We assessed all outcomes at the maximum duration of follow‐up.</p> <section id="CD005162-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD005162-list-0001"> <li> <p>Mortality.</p> </li> <li> <p>Hepatorenal syndrome (number of participants who did not achieve reversal of hepatorenal syndrome). </p> </li> <li> <p>Serious adverse events: any untoward medical occurrence that led to death, was life‐threatening, or required hospitalisation or prolongation of hospitalisation (<a href="./references#CD005162-bbs2-0036" title="International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR &amp; ICH Guidelines. Vol. 1, Philadelphia (PA): Barnett International/PAREXEL, 1997. ">ICH‐GCP 1997</a>). We analysed serious adverse events as a composite outcome (<a href="./references#CD005162-bbs2-0032" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2017, Issue 1. Art. No.: LIVER. ">Gluud 2017</a>). </p> </li> </ol> </p> </section> <section id="CD005162-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD005162-list-0002"> <li> <p>Health‐related quality of life: the overall score based on the quality of life questionnaires used in individual trials. </p> </li> <li> <p>Non‐serious adverse events: all adverse events that did not fulfil the criteria for serious adverse events. </p> </li> </ol> </p> </section> </section> </section> <section id="CD005162-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005162-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We performed electronic searches in the Cochrane Hepato‐Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE (OvidSP), Embase (OvidSP), and Science Citation Index Expanded (Web of Science) (<a href="./references#CD005162-bbs2-0044" title="RoyleP , MilneR . Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care2003;19(4):591‐603. ">Royle 2003</a>). The search strategies with the timespan of the searches are given in <a href="./appendices#CD005162-sec-0102">Appendix 1</a>. We updated searches as of 21 November 2016. </p> </section> <section id="CD005162-sec-0046"> <h4 class="title">Searching other resources</h4> <p>Manual searches included scanning of reference lists in relevant articles and conference proceedings. We also searched trial registers through the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) search portal (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/ictrp/search/en/</a>) (21 November, 2016). </p> </section> </section> <section id="CD005162-sec-0047"> <h3 class="title" id="CD005162-sec-0047">Data collection and analysis</h3> <section id="CD005162-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AA and MI) independently selected trials eligible for inclusion from the updated literature searches and listed excluded with the reasons for exclusion. </p> </section> <section id="CD005162-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (AA and MI) independently extracted data. All disagreements were resolved through discussion before analyses. In case of disagreements, a third review author (LG) acted as ombudsman. We wrote to authors of the included trials to obtain additional information not described in the published reports, including missing data. </p> </section> <section id="CD005162-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias using the domains described in the Cochrane Hepato‐Biliary Group Module (<a href="./references#CD005162-bbs2-0032" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2017, Issue 1. Art. No.: LIVER. ">Gluud 2017</a>). </p> <section id="CD005162-sec-0051"> <h5 class="title">Allocation sequence generation</h5> <p> <ul id="CD005162-list-0003"> <li> <p>Low risk of bias: the study authors performed sequence generation using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if an independent person not otherwise involved in the study performed them. </p> </li> <li> <p>Unclear risk of bias: not specified.</p> </li> <li> <p>High risk of bias: the sequence generation was not random. We planned to include such studies for assessment of harms. </p> </li> </ul> </p> </section> <section id="CD005162-sec-0052"> <h5 class="title">Allocation concealment</h5> <p> <ul id="CD005162-list-0004"> <li> <p>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (e.g. if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes). </p> </li> <li> <p>Unclear risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment. </p> </li> <li> <p>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants. </p> </li> </ul> </p> </section> <section id="CD005162-sec-0053"> <h5 class="title">Blinding of participants and personnel</h5> <p> <ul id="CD005162-list-0005"> <li> <p>Low risk of bias: i) the outcome was mortality, which according to previous empirical evidence is not likely to be influenced by lack of blinding (<a href="./references#CD005162-bbs2-0035" title="HróbjartssonA , GøtzschePC . Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. New England Journal of Medicine2001;344:1594‐602. ">Hróbjartsson 2001</a>; <a href="./references#CD005162-bbs2-0048" title="SavovićJ , JonesH , AltmanD , HarrisR , JűniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assessments2012;16:1‐82. ">Savović 2012</a>); or ii) blinding of participants and key study personnel ensured, and it is unlikely that the blinding could have been broken. </p> </li> <li> <p>Unclear risk of bias: insufficient information to permit judgement of ‘low risk’ or ‘high risk’. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding (non‐mortality outcomes). </p> </li> </ul> </p> </section> <section id="CD005162-sec-0054"> <h5 class="title">Blinding of outcome assessors</h5> <p> <ul id="CD005162-list-0006"> <li> <p>Low risk of bias: i) the outcome was mortality, which according to previous empirical evidence is not likely to be influenced by lack of blinding (<a href="./references#CD005162-bbs2-0035" title="HróbjartssonA , GøtzschePC . Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. New England Journal of Medicine2001;344:1594‐602. ">Hróbjartsson 2001</a>; <a href="./references#CD005162-bbs2-0048" title="SavovićJ , JonesH , AltmanD , HarrisR , JűniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assessments2012;16:1‐82. ">Savović 2012</a>); or ii) blinding of outcome assessment ensured, and it is unlikely that the blinding could have been broken. </p> </li> <li> <p>Unclear risk of bias: insufficient information to permit judgement of ‘low risk’ or ‘high risk’. </p> </li> <li> <p>High risk of bias: no blinding or inadequate blinding (e.g. intravenous versus orally administered drugs), and the outcome is likely to be influenced by lack of blinding (non‐mortality outcomes). </p> </li> </ul> </p> </section> <section id="CD005162-sec-0055"> <h5 class="title">Incomplete outcome data</h5> <p> <ul id="CD005162-list-0007"> <li> <p>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. The investigators used sufficient methods, such as intention‐to‐treat analyses with multiple imputations or carry‐forward analyses, to handle missing data. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data induced bias on the results. </p> </li> <li> <p>High risk of bias: the results were likely to be biased due to missing data.</p> </li> </ul> </p> </section> <section id="CD005162-sec-0056"> <h5 class="title">Selective outcome reporting</h5> <p> <ul id="CD005162-list-0008"> <li> <p>Low risk of bias: the trial reported clinically relevant outcomes (mortality, hepatic encephalopathy, and serious adverse events). If we had access to the original trial protocol, the outcomes should have been those called for in that protocol. If we obtained information from a trial registry (such as <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>), we only used the information if the investigators registered the trial before inclusion of the first participant. </p> </li> <li> <p>Unclear risk of bias: predefined outcomes were not reported fully.</p> </li> <li> <p>High risk of bias: one or more predefined outcomes were not reported.</p> </li> </ul> </p> </section> <section id="CD005162-sec-0057"> <h5 class="title">For‐profit bias</h5> <p> <ul id="CD005162-list-0009"> <li> <p>Low risk of bias: the trial appears to be free of industry sponsorship or other type of for‐profit support. </p> </li> <li> <p>Unclear risk of bias: no information on clinical trial support or sponsorship was available. </p> </li> <li> <p>High risk of bias: the trial was sponsored by industry, received support in the form of terlipressin or placebo, or received any other type of support. </p> </li> </ul> </p> </section> <section id="CD005162-sec-0058"> <h5 class="title">Other bias</h5> <p> <ul id="CD005162-list-0010"> <li> <p>Low risk of bias: the trial appeared to be free of other biases including medicinal dosing problems or follow‐up (as defined below). </p> </li> <li> <p>Unclear risk of bias: the trial may or may not have been free of other factors that could put it at risk of bias. </p> </li> <li> <p>High risk of bias: there were other factors in the trial that could put it at risk of bias, such as the administration of inappropriate treatments to the controls (e.g. an inappropriate dose) or follow‐up (e.g. the trial included different follow‐up schedules for participants in the allocation groups), or premature discontinuation of the trial. </p> </li> </ul> </p> </section> <section id="CD005162-sec-0059"> <h5 class="title">Overall bias assessment</h5> <p> <ul id="CD005162-list-0011"> <li> <p>Low risk of bias: all domains were classified as low risk of bias using the definitions described above. </p> </li> <li> <p>High risk of bias: one or more of the bias domains were classified as unclear or high risk of bias. </p> </li> </ul> </p> </section> </section> <section id="CD005162-sec-0060"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed outcomes using risk ratios (RR) with 95% confidence intervals (CI). For primary outcomes, we calculated the number needed to treat (NNT) using the inverse of the risk difference (RD). Based on the control group event rate, we repeated the analyses using odds ratios (OR) and RD. The analyses using OR and RD had no influence on the results of the review. </p> </section> <section id="CD005162-sec-0061"> <h4 class="title">Unit of analysis issues</h4> <p>We included data from the first treatment period of cross‐over trials.</p> </section> <section id="CD005162-sec-0062"> <h4 class="title">Dealing with missing data</h4> <p>We planned to evaluate the importance of missing data in a worst‐case scenario analysis (with inclusion of missing outcomes as treatment failures) and an extreme worst‐case scenario analysis (including missing outcomes as failures in the experimental group and successes in the control group). However, we did not identify participants with missing outcome data and were therefore unable to conduct these analyses. </p> </section> <section id="CD005162-sec-0063"> <h4 class="title">Assessment of heterogeneity</h4> <p>We expressed heterogeneity as I<sup>2</sup> values using the following thresholds: 0% to 40% (unimportant), 40 to 60% (moderate), 60 to 80% (substantial), and &gt; 80% (considerable). We have included this information in the 'Summary of findings' tables (<a href="./references#CD005162-bbs2-0033" title="BrozekJ , OxmanA , SchünemannH . GRADEpro. Version 3.2 for Windows. Grade Working Group, 2008. ">GRADEpro</a>). </p> </section> <section id="CD005162-sec-0064"> <h4 class="title">Assessment of reporting biases</h4> <p>For meta‐analyses with at least 10 RCTs, we planned to assess reporting biases through regression analyses. </p> </section> <section id="CD005162-sec-0065"> <h4 class="title">Data synthesis</h4> <p>We performed the analyses in Review Manager 5 (<a href="./references#CD005162-bbs2-0043" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), <a href="./references#CD005162-bbs2-0050" title="Stata Corp. STATA. Stata Corp, 2007. ">STATA</a> (<a href="./references#CD005162-bbs2-0050" title="Stata Corp. STATA. Stata Corp, 2007. ">STATA</a>), and Trial Sequential Analysis (<a href="./references#CD005162-bbs2-0051" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011. ">TSA 2011</a>), and used <a href="./references#CD005162-bbs2-0033" title="BrozekJ , OxmanA , SchünemannH . GRADEpro. Version 3.2 for Windows. Grade Working Group, 2008. ">GRADEpro</a> softwareto prepare 'Summary of findings' tables (<a href="./references#CD005162-bbs2-0033" title="BrozekJ , OxmanA , SchünemannH . GRADEpro. Version 3.2 for Windows. Grade Working Group, 2008. ">GRADEpro</a>). </p> <section id="CD005162-sec-0066"> <h5 class="title">Meta‐analysis</h5> <p>We initially conducted fixed‐effect and random‐effects meta‐analyses (<a href="./references#CD005162-bbs2-0034" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). If the estimates of the fixed‐effect and random‐effects meta‐analyses were similar, then we assumed that any small‐study effects had little effect on the intervention effect estimate. If the random‐effects estimate was more beneficial, we planned to re‐evaluate whether it was reasonable to conclude that the intervention was more effective in the smaller studies. We originally planned to evaluate if the larger RCTs tended to be conducted with greater methodological rigour, or conducted in circumstances more typical of the use of terlipressin in clinical practice. Had we found this scenario, we planned to report the results of meta‐analyses restricted to the larger, more rigorous studies. However, this scenario did not occur. </p> <p>Based on the expected clinical heterogeneity, we expected that a number of analyses would display statistical heterogeneity (I<sup>2</sup> &gt; 0%). For random‐effects models, precision will decrease with increasing heterogeneity and confidence intervals will widen correspondingly. We therefore expected that the random‐effects model would give the most conservative (and a more correct) estimate of the intervention effect. Accordingly, we have reported the results of our analyses based on random‐effects meta‐analyses. </p> </section> <section id="CD005162-sec-0067"> <h5 class="title">Trial Sequential Analysis</h5> <p>We performed Trial Sequential Analysis to control the risks of type 1 and type 2 errors and to evaluate futility in the assessment of our primary outcomes (<a href="./references#CD005162-bbs2-0051" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011. ">TSA 2011</a>; <a href="./references#CD005162-bbs2-0032" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2017, Issue 1. Art. No.: LIVER. ">Gluud 2017</a>). We defined the required information size (also known as the diversity‐adjusted required information size) as the number of participants needed to detect or reject an intervention effect based on the relative risk reduction (RRR) and control group risk (CGR). Firm evidence was established if the Z‐curve crossed the monitoring boundary (also known as the trial sequential monitoring boundary) before reaching the required information size. Based on previous evidence (<a href="./references#CD005162-bbs2-0039" title="KragA , BorupT , MøllerS , BendtsenF . Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Advances in Therapy2008;25:1105‐40. ">Krag 2008</a>), we performed the analyses with alpha set to 3%, power to 90%, and the RRR, CGR, and heterogeneity correction to 25%, 61.5%, and 30% for mortality; 25%, 87.5%, and 70% for hepatorenal syndrome; and 25%, 15%, and 20% for serious cardiovascular adverse events. We repeated the analyses with the RRR reduced to 20% for mortality, hepatorenal syndrome, and serious cardiovascular adverse events. In the analyses of serious cardiovascular events, we also reduced the CGR to 5%. </p> </section> </section> <section id="CD005162-sec-0068"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted subgroup analyses to investigate heterogeneity associated with the type of hepatorenal syndrome and use of albumin. </p> </section> <section id="CD005162-sec-0069"> <h4 class="title">Sensitivity analysis</h4> <p>We did not evaluate the influence of bias because only one RCT was at low risk of bias for mortality and no randomised clinical trials were at low risk of bias for the remaining outcomes. </p> <section id="CD005162-sec-0070"> <h5 class="title">Summary of findings tables</h5> <p>We used <a href="./references#CD005162-bbs2-0033" title="BrozekJ , OxmanA , SchünemannH . GRADEpro. Version 3.2 for Windows. Grade Working Group, 2008. ">GRADEpro</a> to generate a 'Summary of findings' table with information about outcomes, risk of bias, and the results of the meta‐analyses (<a href="./references#CD005162-bbs2-0033" title="BrozekJ , OxmanA , SchünemannH . GRADEpro. Version 3.2 for Windows. Grade Working Group, 2008. ">GRADEpro</a>). We used the GRADE system to evaluate the quality of the evidence for outcomes reported in the review considering the within‐study risk of bias (methodological quality), indirectness of evidence, heterogeneity, imprecision of effect estimate, and risk of publication bias. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005162-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005162-sec-0071"></div> <section id="CD005162-sec-0072"> <h3 class="title">Description of studies</h3> <p>We included nine randomised clinical trials in the quantitative and qualitative analyses (see <a href="./references#CD005162-sec-0111" title="">Characteristics of included studies</a>). We also identified one ongoing trial (<a href="./references#CD005162-bbs2-0021" title="A placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin. Ongoing studySeptember 2010. ">NCT01143246</a>). </p> <section id="CD005162-sec-0073"> <h4 class="title">Results of the search</h4> <p>The electronic searches revealed 619 potentially eligible references and the manual searches three additional references (<a href="#CD005162-fig-0001">Figure 1</a>). After scanning the titles and abstracts, we retrieved and listed 25 records. We had to exclude 10 of these that referred to randomised clinical trials on participants with hepatorenal syndrome because they did not evaluate the interventions assessed in the present review (<a href="./references#CD005162-bbs2-0014" title="ChelarescuD , ChelarescuO , CrumpieF , StaratanI . Captopril in low dose associated with octreotide in hepatorenal syndrome: a randomized study. Journal of Hepatology2003;38:S56. ">Chelarescu 2003</a>; <a href="./references#CD005162-bbs2-0017" title="Pomier‐LayrarguesG , PaquinSC , HassounZ , LafortuneM , TranA . Octreotide in hepatorenal syndrome: a randomized, double‐blind, placebo‐controlled, crossover study. Hepatology (Baltimore, Md.)2003;38:238‐43. ">Pomier 2003</a>; <a href="./references#CD005162-bbs2-0010" title="AlessandriaC , MarzanoA , OttobrelliA , Debernardi‐VenonW , TodrosL , TorrniM , et al. Noradrenaline vs terlipressin in hepatorenal syndrome: a prospective, randomized study. Journal of Hepatology2006;44:S83. AlessandriaC , OttobrelliA , Debernardi‐VenonW , TodrosL , CerenziaMT , MartiniS , et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. Journal of Hepatology2007;47:499‐505. ">Alessandria 2007</a>; <a href="./references#CD005162-bbs2-0011" title="AngeliP , FasolatoS , CavallinM , MaresioG , CallegaroA , SticcaA , et al. Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type 1 hepatorenal syndrome (HRS) in patients with cirrhosis: results of a controlled clinical study. Hepatology (Baltimore, Md.)2008;48:378A. ">Angeli 2008</a>; <a href="./references#CD005162-bbs2-0018" title="SharmaP , KumarA , ShramaBC , SarinSK . An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. American Journal of Gastroenterology2008;103:1689‐97. SharmaP , KumarA , ShramaBC , SarinSK . Noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome: a randomized controlled trial. Hepatology (Baltimore, Md.)2006;44:449A. ">Sharma 2008</a>; <a href="./references#CD005162-bbs2-0019" title="SilawatFN , ShaikhMK , LohanaRK , DevrajaniBR , ShahSZA , AnsariA . Efficacy of terlipressin and albumin in the treatment of hepatorenal syndrome. World Applied Sciences Journal2011;12(11):1946‐59. ">Silawat 2011</a>; <a href="./references#CD005162-bbs2-0012" title="CavallinM , MerliM , FasolatoS , ToniuttoP , SalernoF , BernardiM , et al. Terlipressin and albumin vs midodrine plus octreotide in the treatment of hepatorenal syndrome in patients with cirrhosis: results of a controlled trial by the Italian Association for the Study of the Liver. Digestive and Liver Disease2012;44:S10. ">Cavallin 2012</a>; <a href="./references#CD005162-bbs2-0015" title="IndrabiRA , ZargarGJSA , KhanBA , YattooGN , ShahSH , GulzarBM , et al. Noradrenaline is equally effective as terlipressin in reversal of type 1 hepatorenal syndrome: a randomized prospective study. Journal of Clinical and Experimental Hepatology2013;3:S97. ">Indrabi 2013</a>; <a href="./references#CD005162-bbs2-0020" title="WanS , WanX , ZhuQ , PengJ . A comparative study of high‐ or low‐dose terlipressin therapy in patients with cirrhosis and type 1 hepatorenal syndrome [高低剂量特利加压素治疗肝硬化合并1型肝肾综合征的比较]. Zhonghua Gan Zang Bing Za Zhi2014;21:35. ">Wan 2014</a>; <a href="./references#CD005162-bbs2-0013" title="CavallinM , KamathPS , MerliM , FasolatoS , ToniuttoP , SalernoF , et al. Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology (Baltimore, Md.)2015;62:567‐74. ">Cavallin 2015</a>; <a href="./references#CD005162-bbs2-0016" title="Nguyen‐TatM , GötzE , Scholz‐KreiselP , AhrensJ , SivanathanV , SchattenbergJ , et al. Response to terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome [Leberzirrhose und hepatorenales Syndrom: Das Ansprechen auf Terlipressin und Albumin ist mit besserem Überleben assoziiert]. Deutsche Medizinische Wochenschrift2015;140:21‐6. ">Nguyen‐Tat 2015</a>). The remaining references referred to nine RCTs that fulfilled our inclusion criteria (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>; <a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>; <a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0005" title="PulvirentiD , TsamiA . Low doses of terlipressin and albumin in type I hepatorenal syndrome [Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I]. Italian Journal of Medicine2008;2:34‐8. ">Pulvirenti 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>; <a href="./references#CD005162-bbs2-0001" title="BoyerTD , MedicisJJ , PappasSC , PotenzianoJ , JamilK . A randomized, placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials2012;4:39‐49. BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016; Vol. 150, issue 7:1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>). One trial used a cross‐over design (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>), and the remaining a parallel‐group design (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>; <a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0005" title="PulvirentiD , TsamiA . Low doses of terlipressin and albumin in type I hepatorenal syndrome [Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I]. Italian Journal of Medicine2008;2:34‐8. ">Pulvirenti 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>; <a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>; <a href="./references#CD005162-bbs2-0001" title="BoyerTD , MedicisJJ , PappasSC , PotenzianoJ , JamilK . A randomized, placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials2012;4:39‐49. BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016; Vol. 150, issue 7:1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>). </p> <div class="figure" id="CD005162-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD005162-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD005162-sec-0074"> <h4 class="title">Included studies</h4> <section id="CD005162-sec-0075"> <h5 class="title">Trial characteristics</h5> <p>One RCT was published in abstract form (<a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>) and the remaining RCTs as full‐paper articles (<a href="./references#CD005162-sec-0111" title="">Characteristics of included studies</a>). The language of trial publications was Chinese (<a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>), Italian (<a href="./references#CD005162-bbs2-0005" title="PulvirentiD , TsamiA . Low doses of terlipressin and albumin in type I hepatorenal syndrome [Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I]. Italian Journal of Medicine2008;2:34‐8. ">Pulvirenti 2008</a>), or English (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>; <a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>; <a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>; <a href="./references#CD005162-bbs2-0001" title="BoyerTD , MedicisJJ , PappasSC , PotenzianoJ , JamilK . A randomized, placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials2012;4:39‐49. BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016; Vol. 150, issue 7:1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>). The trials were conducted in the United States, Italy, Spain, Canada, India, China, Germany, and Russia. The trial investigators performed the trials in specialised units in an intensive or semi‐intensive setting. Three trials were multicenter trials (<a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>; <a href="./references#CD005162-bbs2-0001" title="BoyerTD , MedicisJJ , PappasSC , PotenzianoJ , JamilK . A randomized, placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials2012;4:39‐49. BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016; Vol. 150, issue 7:1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>), and the remaining trials were single‐centre trials (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>; <a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>; <a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0005" title="PulvirentiD , TsamiA . Low doses of terlipressin and albumin in type I hepatorenal syndrome [Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I]. Italian Journal of Medicine2008;2:34‐8. ">Pulvirenti 2008</a>; <a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>). </p> <p>The duration of follow‐up was six months in two trials (<a href="./references#CD005162-bbs2-0005" title="PulvirentiD , TsamiA . Low doses of terlipressin and albumin in type I hepatorenal syndrome [Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I]. Italian Journal of Medicine2008;2:34‐8. ">Pulvirenti 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>), three months in one RCT (<a href="./references#CD005162-bbs2-0001" title="BoyerTD , MedicisJJ , PappasSC , PotenzianoJ , JamilK . A randomized, placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials2012;4:39‐49. BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016; Vol. 150, issue 7:1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>), and end of treatment in the remaining trials (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>; <a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>; <a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>). </p> </section> <section id="CD005162-sec-0076"> <h5 class="title">Participant characteristics</h5> <p>The total number of participants was 534 participants. Included participants had cirrhosis, ascites, and hepatorenal syndrome with serum creatinine &gt; 133 µmol/L (1.5 mg/dL) after diuretic withdrawal and volume expansion. None of the participants had evidence of shock, parenchymal renal disease, treatment with nephrotoxic drugs, or other potential causes of kidney disease. In total, 473 participants had type 1 hepatorenal syndrome. One RCT included 11 participants with type 2 hepatorenal syndrome (<a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>). One RCT with 50 participants did not describe if participants had type 1 or type 2 hepatorenal syndrome (<a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>). The mean age in the terlipressin and control groups ranged from 51 to 59 years and 52 to 60 years. The proportion of men ranged from 40% to 71%, and the proportion with alcoholic liver disease from 13% to 72%. </p> </section> <section id="CD005162-sec-0077"> <h5 class="title">Intervention characteristics</h5> <p>The median initial dose of terlipressin was 1 mg four times daily. The RCTs used a fixed dose of terlipressin (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>; <a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>; <a href="./references#CD005162-bbs2-0005" title="PulvirentiD , TsamiA . Low doses of terlipressin and albumin in type I hepatorenal syndrome [Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I]. Italian Journal of Medicine2008;2:34‐8. ">Pulvirenti 2008</a>), or increased the dose after three days in non‐responders to a maximum of 2 mg four to six times daily (<a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>; <a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>; <a href="./references#CD005162-bbs2-0001" title="BoyerTD , MedicisJJ , PappasSC , PotenzianoJ , JamilK . A randomized, placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials2012;4:39‐49. BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016; Vol. 150, issue 7:1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>). One trial used continuous administration of terlipressin for the first day before switching to bolus dosing (<a href="./references#CD005162-bbs2-0005" title="PulvirentiD , TsamiA . Low doses of terlipressin and albumin in type I hepatorenal syndrome [Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I]. Italian Journal of Medicine2008;2:34‐8. ">Pulvirenti 2008</a>). The duration of terlipressin administration ranged from two days, in <a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>, to 19 days, in <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>, with a median treatment duration of 15 days. Two trials did not use albumin (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>). All participants in the experimental and control groups of the remaining trials received comparable albumin (<a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>; <a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0005" title="PulvirentiD , TsamiA . Low doses of terlipressin and albumin in type I hepatorenal syndrome [Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I]. Italian Journal of Medicine2008;2:34‐8. ">Pulvirenti 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>; <a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>; <a href="./references#CD005162-bbs2-0001" title="BoyerTD , MedicisJJ , PappasSC , PotenzianoJ , JamilK . A randomized, placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials2012;4:39‐49. BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016; Vol. 150, issue 7:1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>). </p> </section> </section> <section id="CD005162-sec-0078"> <h4 class="title">Excluded studies</h4> <p>The excluded RCTs compared terlipressin and albumin versus other vasoactive drugs for hepatorenal syndrome (see <a href="./references#CD005162-sec-0112" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD005162-sec-0079"> <h3 class="title">Risk of bias in included studies</h3> <p>We identified several sources of bias (<a href="#CD005162-fig-0002">Figure 2</a>). For the outcome mortality, we classified one trial as at 'low risk of bias' <a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>, and the remaining trials as at 'high risk of bias' (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>; <a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0005" title="PulvirentiD , TsamiA . Low doses of terlipressin and albumin in type I hepatorenal syndrome [Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I]. Italian Journal of Medicine2008;2:34‐8. ">Pulvirenti 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>; <a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>; <a href="./references#CD005162-bbs2-0001" title="BoyerTD , MedicisJJ , PappasSC , PotenzianoJ , JamilK . A randomized, placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials2012;4:39‐49. BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016; Vol. 150, issue 7:1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>). For non‐mortality outcomes, we classified all RCTs as at 'high risk of bias'. No single study lacked bias across all assessed domains, including randomisation/sequence allocation, blinding, and for‐profit funding sources. We deemed <a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a> as at 'low risk of bias' for mortality because its sources of bias were only around blinding, which was less likely to have an influence on a purely objective outcome like mortality. </p> <div class="figure" id="CD005162-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgments about each methodological quality item for each included study." data-id="CD005162-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgments about each methodological quality item for each included study. </p> </div> </div> </div> <p><a href="#CD005162-fig-0003">Figure 3</a> presents review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> <div class="figure" id="CD005162-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005162-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD005162-sec-0080"> <h4 class="title">Allocation</h4> <p>Three RCTs did not describe the allocation sequence generation (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>; <a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>), and two RCTs did not describe the allocation concealment (<a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>; <a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>). Accordingly, we classified six RCTs as 'low risk' of selection bias (<a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>; <a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0005" title="PulvirentiD , TsamiA . Low doses of terlipressin and albumin in type I hepatorenal syndrome [Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I]. Italian Journal of Medicine2008;2:34‐8. ">Pulvirenti 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>; <a href="./references#CD005162-bbs2-0001" title="BoyerTD , MedicisJJ , PappasSC , PotenzianoJ , JamilK . A randomized, placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials2012;4:39‐49. BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016; Vol. 150, issue 7:1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>). </p> </section> <section id="CD005162-sec-0081"> <h4 class="title">Blinding</h4> <p>We considered tree RCTs that were double‐blind as as 'low risk' of performance and detection bias (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>; <a href="./references#CD005162-bbs2-0001" title="BoyerTD , MedicisJJ , PappasSC , PotenzianoJ , JamilK . A randomized, placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials2012;4:39‐49. BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016; Vol. 150, issue 7:1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>). We assessed the remaining RCTsas 'unclear', <a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>, or 'high risk' of performance and detection bias (<a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>; <a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0005" title="PulvirentiD , TsamiA . Low doses of terlipressin and albumin in type I hepatorenal syndrome [Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I]. Italian Journal of Medicine2008;2:34‐8. ">Pulvirenti 2008</a>; <a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>). </p> </section> <section id="CD005162-sec-0082"> <h4 class="title">Incomplete outcome data</h4> <p>Six RCTs had no missing outcome data and included all participants in the analyses (<a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>; <a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0005" title="PulvirentiD , TsamiA . Low doses of terlipressin and albumin in type I hepatorenal syndrome [Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I]. Italian Journal of Medicine2008;2:34‐8. ">Pulvirenti 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>; <a href="./references#CD005162-bbs2-0001" title="BoyerTD , MedicisJJ , PappasSC , PotenzianoJ , JamilK . A randomized, placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials2012;4:39‐49. BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016; Vol. 150, issue 7:1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>). We classified these RCTs as low risk of attrition bias and the remaining three RCTs as 'unclear risk', <a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>, <a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>, or 'high risk' of attrition bias (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>). </p> </section> <section id="CD005162-sec-0083"> <h4 class="title">Selective reporting</h4> <p>All RCTs reported clinically relevant outcomes (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>; <a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>; <a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0005" title="PulvirentiD , TsamiA . Low doses of terlipressin and albumin in type I hepatorenal syndrome [Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I]. Italian Journal of Medicine2008;2:34‐8. ">Pulvirenti 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>; <a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>; <a href="./references#CD005162-bbs2-0001" title="BoyerTD , MedicisJJ , PappasSC , PotenzianoJ , JamilK . A randomized, placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials2012;4:39‐49. BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016; Vol. 150, issue 7:1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>). We identified no discrepancies between registered protocols (for those available) and trial publications. </p> <section id="CD005162-sec-0084"> <h5 class="title">For‐profit funding</h5> <p>One RCT did not receive external funding (<a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>). Three RCTs received funding from a pharmaceutical company (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>; <a href="./references#CD005162-bbs2-0001" title="BoyerTD , MedicisJJ , PappasSC , PotenzianoJ , JamilK . A randomized, placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials2012;4:39‐49. BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016; Vol. 150, issue 7:1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>). The remaining RCTs did not report funding (<a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>; <a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0005" title="PulvirentiD , TsamiA . Low doses of terlipressin and albumin in type I hepatorenal syndrome [Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I]. Italian Journal of Medicine2008;2:34‐8. ">Pulvirenti 2008</a>; <a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>). </p> </section> </section> <section id="CD005162-sec-0085"> <h4 class="title">Other potential sources of bias</h4> <p>One study was stopped early due to low event rates (<a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>). </p> </section> </section> <section id="CD005162-sec-0086"> <h3 class="title" id="CD005162-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD005162-tbl-0001"><b>Summary of findings for the main comparison</b> Terlipressin versus placebo or no intervention for hepatorenal syndrome</a> </p> <section id="CD005162-sec-0087"> <h4 class="title">Primary outcomes</h4> <p>We were able to gather mortality data from all RCTs (<a href="./references#CD005162-fig-0007" title="">Analysis 1.1</a>). Terlipressin was associated with reduced mortality compared with placebo/no intervention when including all RCTs (risk ratio (RR) 0.85, 95% confidence interval (CI) 0.73 to 0.98; 534 participants; 9 RCTs; I<sup>2</sup> = 14%; number needed to treat for an additional beneficial outcome (NNTB) to prevent one death was 10; low‐quality evidence). In Trial Sequential Analysis including all RCTs (<a href="#CD005162-fig-0004">Figure 4</a>), the cumulative Z‐curve did not cross the monitoring boundary for benefit. We planned to conduct worst‐case scenario analyses. However, as six of the included RCTs did not have missing outcome data (<a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>; <a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0005" title="PulvirentiD , TsamiA . Low doses of terlipressin and albumin in type I hepatorenal syndrome [Terlipressina a basso dosaggio e albuminanella sindrome epatorenale di tipo I]. Italian Journal of Medicine2008;2:34‐8. ">Pulvirenti 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>; <a href="./references#CD005162-bbs2-0001" title="BoyerTD , MedicisJJ , PappasSC , PotenzianoJ , JamilK . A randomized, placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials2012;4:39‐49. BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016; Vol. 150, issue 7:1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>), and we were unable to extract the number of participants with missing outcomes from the remaining three RCTs (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>; <a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>), we were therefore unable to conduct the analysis. Subgroup analyses found an effect of terlipressin in the RCTs evaluating type 1 hepatorenal syndrome (RR 0.78, 95% CI 0.63 to 0.98; 438 participants; 7 RCT; I<sup>2</sup> = 30%; <a href="./references#CD005162-fig-0007" title="">Analysis 1.1</a>). We were unable to gather separate outcome data on participants with type 1 or type 2 hepatorenal syndrome from two RCTs (RR 0.92, 95% CI 0.75 to 1.14; 96 participants; I<sup>2</sup> = 0%). An additional subgroup analysis found no beneficial or harmful effect of the terlipressin and albumin (RR 0.82, 95% CI 0.67 to 1.01; 510 participants; I<sup>2</sup> = 22%; <a href="./references#CD005162-fig-0008" title="">Analysis 1.2</a>). </p> <div class="figure" id="CD005162-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of eight randomised clinical trials (525 participants) evaluating terlipressin versus placebo or no intervention for people with hepatorenal syndrome on mortality. Data from Hadengue 1998 is not included due to lack of events. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group risk (CGR) of mortality of 61.5%, and a model variance ‐based heterogeneity correction of 30%. The risk ratio is 0.85 (95% confidence interval 0.70 to 1.02). The cumulative Z‐curve (blue line) does not cross the diversity‐adjusted trial monitoring boundary for benefit." data-id="CD005162-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of eight randomised clinical trials (525 participants) evaluating terlipressin versus placebo or no intervention for people with hepatorenal syndrome on mortality. Data from <a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a> is not included due to lack of events. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group risk (CGR) of mortality of 61.5%, and a model variance ‐based heterogeneity correction of 30%. The risk ratio is 0.85 (95% confidence interval 0.70 to 1.02). The cumulative Z‐curve (blue line) does not cross the diversity‐adjusted trial monitoring boundary for benefit. </p> </div> </div> </div> <p>Two RCTs did not report the number of participants without reversal of hepatorenal syndrome (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>). Analysis of the remaining seven RCTs showed a beneficial effect of terlipressin on this outcome measure (RR 0.63, 95% CI 0.48 to 0.82; 510 participants; I<sup>2</sup> = 75%; low‐quality evidence; <a href="./references#CD005162-fig-0009" title="">Analysis 1.3</a>). In Trial Sequential Analysis including these seven RCTs (<a href="#CD005162-fig-0005">Figure 5</a>), the cumulative Z score crossed the monitoring boundary for benefit.The NNTB to reverse one case of hepatorenal syndrome was 4. All RCTs included in this analysis evaluated terlipressin and albumin. In Trial Sequential Analysis including all RCTs regardless of bias control (<a href="#CD005162-fig-0006">Figure 6</a>), the cumulative Z‐curve crossed the monitoring boundary for benefit. Subgroup analyses showed a beneficial effect of terlipressin on type 1 hepatorenal syndrome based on six RCTs (RR 0.64, 95% CI 0.47 to 0.87; 449 participants; I<sup>2</sup> = 80%), but not in participants with type 2 hepatorenal syndrome (RR 0.39, 95% CI 0.14 to 1.08; 11 participants; 1 RCT) or the trial including participants with type 1 or type 2 hepatorenal syndrome (RR 0.65, 95% CI 0.46 to 0.92; 50 participants). </p> <div class="figure" id="CD005162-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of seven randomised clinical trials (510 participants) evaluating terlipressin versus placebo/no intervention for people with hepatorenal syndrome on lack of reversal of hepatorenal syndrome. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group risk (CGR) of lack of reversal of hepatorenal syndrome of 88%, and a heterogeneity correction of 70%. The risk ratio is 0.64 (95% confidence interval 0.46 to 0.89). The cumulative Z‐curve (blue line) crosses the diversity‐adjusted trial monitoring boundary for benefit during the fourth trial." data-id="CD005162-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of seven randomised clinical trials (510 participants) evaluating terlipressin versus placebo/no intervention for people with hepatorenal syndrome on lack of reversal of hepatorenal syndrome. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group risk (CGR) of lack of reversal of hepatorenal syndrome of 88%, and a heterogeneity correction of 70%. The risk ratio is 0.64 (95% confidence interval 0.46 to 0.89). The cumulative Z‐curve (blue line) crosses the diversity‐adjusted trial monitoring boundary for benefit during the fourth trial. </p> </div> </div> </div> <div class="figure" id="CD005162-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of four randomised clinical trials (234 participants) evaluating terlipressin versus placebo or no intervention for people with hepatorenal syndrome on cardiovascular adverse events. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group risk (CGR) of cardiovascular adverse events of 15%, and a heterogeneity correction of 20%. The risk ratio is 7.26 (95% confidence interval 1.70 to 31.05). The diversity‐adjusted trial monitoring boundary for harm is not included in the figure due to insufficient information. The estimated required information size is 4831 participants. Accordingly, with an accrued number of participants of 234, only 4.8% of the required number of participants has been achieved." data-id="CD005162-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of four randomised clinical trials (234 participants) evaluating terlipressin versus placebo or no intervention for people with hepatorenal syndrome on cardiovascular adverse events. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group risk (CGR) of cardiovascular adverse events of 15%, and a heterogeneity correction of 20%. The risk ratio is 7.26 (95% confidence interval 1.70 to 31.05). The diversity‐adjusted trial monitoring boundary for harm is not included in the figure due to insufficient information. The estimated required information size is 4831 participants. Accordingly, with an accrued number of participants of 234, only 4.8% of the required number of participants has been achieved. </p> </div> </div> </div> <p>Overall, terlipressin did not influence the risk of serious adverse events when analysed as a composite outcome (RR 0.91, 95% CI 0.68 to 1.21; participants = 534; 9 RCTs; I<sup>2</sup> = 71%; <a href="./references#CD005162-fig-0010" title="">Analysis 1.4</a>). The number needed to treat for an additional harmful outcome to cause one serious adverse event was 24.5. A Trial Sequential Analysis also found a detrimental effect of terlipressin on this outcome (<a href="#CD005162-fig-0006">Figure 6</a>). As expected, the most common serious adverse events were cardiovascular (RR 7.26, 95% CI 1.70 to 31.05; <a href="./references#CD005162-fig-0011" title="">Analysis 1.5</a>). Other serious adverse events included circulatory overload, gastrointestinal bleeding, hepatic encephalopathy, respiratory distress/acidosis, and bacterial infections. </p> <p>We repeated the Trial Sequential Analyses with power increased to 90% and the relative risk reduction reduced to 10% for mortality and 20% for hepatorenal syndrome and serious cardiovascular adverse events. In the analyses of serious cardiovascular events, we also reduced the control group risk to 15%. All analyses found insufficient evidence to support or refute beneficial or harmful effects of terlipressin versus placebo/no intervention. </p> </section> <section id="CD005162-sec-0088"> <h4 class="title">Secondary outcomes</h4> <p>None of the included trials assessed health‐related quality of life. Non‐serious adverse events were similar when comparing terlipressin with placebo or no intervention (RR 1.25, 95% CI 0.58 to 2.68; 406 participants; 5 RCTs; I<sup>2</sup> = 17%; <a href="./references#CD005162-fig-0012" title="">Analysis 1.6</a>). The most frequent adverse events were gastrointestinal, including abdominal pain and diarrhoea. </p> </section> <section id="CD005162-sec-0089"> <h4 class="title">Quality of the evidence</h4> <p>We downgraded the quality of the evidence for all outcomes due to risk of bias, clinical heterogeneity, and imprecision according to the Trial Sequential Analyses (<a href="./full#CD005162-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005162-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005162-sec-0090"></div> <section id="CD005162-sec-0091"> <h3 class="title" id="CD005162-sec-0091">Summary of main results</h3> <p>This review found that terlipressin may reduce mortality and have a beneficial effect on renal function in type 1 hepatorenal syndrome, but an increased risk of serious cardiovascular adverse events was also noted. Other studies also show that terlipressin may be associated with severe adverse effects (<a href="./references#CD005162-bbs2-0049" title="ShawcrossDL , DaviesNA , MookerjeeRP , HayesPC , WilliamsR , LeeA , et al. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. Hepatology (Baltimore, Md.)2004;39:471‐5. ">Shawcross 2004</a>; <a href="./references#CD005162-bbs2-0039" title="KragA , BorupT , MøllerS , BendtsenF . Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Advances in Therapy2008;25:1105‐40. ">Krag 2008</a>), therefore the intervention should be closely monitored. In addition, only one RCT had a low risk of bias in the overall assessment and most of the included RCTs only followed participants to the end of treatment. Accordingly, the quality of the evidence was low and additional RCTs may be needed. </p> <p>The evidence on the use of terlipressin alone and intervention benefits in type 2 hepatorenal syndrome was scarce. Only two of the included trials assessed terlipressin alone (<a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>; <a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>); the trials were small and the findings were inconclusive. Likewise, only two RCTs on terlipressin included participants with type 2 hepatorenal syndrome (<a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0009" title="ZafarS , HaqueI , UnTayyabG , KhanG , ChaudryN . Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome. American Journal of Gastroenterology2012;107:S175. ">Zafar 2012</a>), and the number of participants with type 2 hepatorenal syndrome was relatively small. Accordingly, we identified no clear intervention effects for this patient group. </p> </section> <section id="CD005162-sec-0092"> <h3 class="title" id="CD005162-sec-0092">Overall completeness and applicability of evidence</h3> <p>We found little evidence of clinical intertrial heterogeneity. The mean control group Child‐Pugh scores were remarkably similar (11 in three trials) (<a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>). Likewise, the included trials used similar criteria to diagnose hepatorenal syndrome, based on previous recommendations (<a href="./references#CD005162-bbs2-0023" title="ArroyoV , GinesP , GerbesAL , DudleyFJ , GentiliniP , LaffiG , et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology (Baltimore, Md.)1996;23:164‐76. ">Arroyo 1996</a>). Diagnostic criteria included presence of cirrhosis, ascites, elevated serum creatinine after at least 48 hours of diuretic withdrawal and volume expansion combined with absence of shock, treatment with nephrotoxic drugs, and parenchymal renal disease (<a href="./references#CD005162-bbs2-0047" title="SalernoF , GerbesA , GinèsP , WongF , ArroyoV . Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut2007;56:1310‐8. ">Salerno 2007</a>). Updated criteria in 2015 now use a lower threshold of increased creatinine to diagnose hepatorenal syndrome (<a href="./references#CD005162-bbs2-0022" title="AngeliP , GinesP , WongF , BernardiM , BoyerTD , GerbesA , et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Journal of Hepatology2015;62:968‐74. [PUBMED: 25638527] ">Angeli 2015</a>). Less emphasis is placed on the labels of type 1 hepatorenal syndrome (defined as serum creatinine increasing to 226 µmol/L (2.5 mg/dL) within two weeks) and type 2 hepatorenal syndrome (defined as a moderate to slowly progressive renal failure with serum creatinine between 133 and 226 µmol/L (1.5 to 2.5 mg/dL)). Although the included trials used previously established criteria, the evidence is likely to be applicable today. However, it may be argued that there is still room for trials on terlipressin using the current diagnostic criteria, as the current criteria are more sensitive to detection of less severe acute kidney injury. Future trials would likely benefit from adoption of a standardised treatment algorithm of terlipressin dosing and sample‐sized calculations based on mortality rates, rather than rates of reversal of hepatorenal syndrome. Notably, dosing of intravenous terlipressin varied widely among studies, ranging from 1 mg twice daily, in <a href="./references#CD005162-bbs2-0008" title="YangYZ , DanZL , LinNZ , LinM , LiangKH . Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome. Journal of Internal Intensive Medicine2001;7:123‐5. ">Yang 2001</a>, to up to 2 mg six times per day for non‐responders in <a href="./references#CD005162-bbs2-0001" title="BoyerTD , MedicisJJ , PappasSC , PotenzianoJ , JamilK . A randomized, placebo‐controlled, double‐blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials2012;4:39‐49. BoyerTD , SanyalAJ , WongF , FrederickRT , LakeJR , O'LearyJG , et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology2016; Vol. 150, issue 7:1579‐89.e2. [PUBMED: 26896734] ">Boyer 2016</a>, thus making direct comparisons between trials more challenging. </p> <p>The duration of the effect of terlipressin on mortality should be considered when deciding whether or not to treat a patient with hepatorenal syndrome (<a href="./references#CD005162-bbs2-0054" title="GluudLL , ChristensenK , ChristensenE , KragA . Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology (Baltimore, Md.)2010;51(2):576‐84. [DOI: 10.1002/hep.23286] ">Gluud 2010</a>). Some participants may die in spite of a clear improvement in renal function (<a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>). The duration of treatment varied among the included trials, ranging from two days, in <a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a>, to 19 days, in <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>, with a median duration of 15 days. This may affect the intervention effect estimates. After an initial complete normalisation of renal function, hepatorenal syndrome may reappear. We attempted to perform a post hoc analysis to determine the effect of treatment on recurrence of hepatorenal syndrome but were unable to extract the necessary data. </p> </section> <section id="CD005162-sec-0093"> <h3 class="title" id="CD005162-sec-0093">Quality of the evidence</h3> <p>The present review identified a number of methodological concerns, including lack of sample size calculations, unclear randomisation, and lack of blinding. We downgraded evidence due to high risk of bias within individual trials, heterogeneity across trials, and imprecision (wide confidence intervals) of outcomes. As a result, the evidence for each of the primary and secondary analyses received a low quality rating. One of the included trials reporting sample size calculations was terminated prematurely due to unexpectedly low event rates (<a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>). The trial assessed terlipressin plus albumin versus albumin and was terminated after an interim analysis suggested that 2000 participants would be required to achieve sufficient statistical power. Whether the interim results reflect a true (low) intervention effect, a random error, or the inclusion criteria is difficult to assess. One possible explanation could be that a number of the included participants had type 2 hepatorenal syndrome; overall, there is little evidence on this patient group. </p> </section> <section id="CD005162-sec-0094"> <h3 class="title" id="CD005162-sec-0094">Potential biases in the review process</h3> <p>One of the main limitations of the present review concerns the relatively low overall sample size. Identification of participants who clearly fulfil the diagnostic criteria for hepatorenal syndrome may be difficult, as is the recruitment of critically ill people in clinical trials. Accordingly, the largest trials were multicentred and multinational (<a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>). This involvement of several clinical sites in more than one geographical region increases the clinical heterogeneity. On the other hand, the heterogeneity also increases the external validity, making it possible to extrapolate the results to larger patient populations in similar specialised centres. The heterogeneity increases the need for additional subgroup and sensitivity analyses. Analysis of individual patient data would have increased the possibilities of performing such analyses. Unfortunately, the available data did not allow detailed analyses of potential sources of heterogeneity. In addition, we have reversed the definition of an event in <a href="./references#CD005162-fig-0009" title="">Analysis 1.3</a> compared to prior versions of this review, which resulted in a high event rate, potentially introducing bias through the use of risk ratios as our effect measure. We felt the analysis of 'reversal of hepatorenal syndrome' was easier to interpret clinically than 'non‐reversal'. This also obviated the need to perform a separate analysis for 'improvement in renal function'. </p> <p>We did not search specifically for harms reported in quasi‐randomised and observational studies, which is a weakness of this review that may bias our assessments of the balance between benefits and harms. </p> <p>We did not search databases of regulatory authorities, and so may have overlooked unpublished trials. This could also have hampered our assessments of the balance between benefits and harms. </p> </section> <section id="CD005162-sec-0095"> <h3 class="title" id="CD005162-sec-0095">Agreements and disagreements with other studies or reviews</h3> <p>Three of the included trials found that baseline serum creatinine was an independent predictor of survival (<a href="./references#CD005162-bbs2-0003" title="Martin‐LlahiM , PepinMN , GuevaraM , TorreA , MonescilloA , SorianoG , et al. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology2007;46:S36. Martín‐LlahíM , PépinMN , GuevaraM , DíazF , TorreA , MonescilloA , et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology2008;134:1352‐9. [ClinicalTrials.gov NCT00287664] ">Martín‐Llahí 2008</a>; <a href="./references#CD005162-bbs2-0004" title="NeriS , PulvirentiD , MalaguarneraM , CosimoBM , BertinoG , IgnaccoloL , et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Digestive Diseases and Sciences2008;53:830‐5. [PUBMED: 17939047] ">Neri 2008</a>; <a href="./references#CD005162-bbs2-0006" title="SanyalA , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , TeuberP . A prospective, randomized, double blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology (Baltimore, Md.)2006;44:694A. SanyalAJ , BoyerT , Garcia‐TsaoG , RegensteinF , RossaroL , AppenrodtB , et al. A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008;134:1360‐8. [MEDLINE: 18471513; ClinicalTrials.gov NCT00089570] SanyalAJ , BoyerTD , Garcia‐TsaoG , BleiAT , TeuberP , Terlipressin Study Group. Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial. Hepatology (Baltimore, Md.)2008;48:1071A. SanyalAJ , BoyerTD , TeuberP . Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double‐blind, placebo‐controlled trial. Hepatology (Baltimore, Md.)2007;46:565A. ">Sanyal 2008</a>). In our analyses, the baseline creatinine in the control groups of the trials on terlipressin plus albumin ranged from 194 to 362 µmol/L (2.2 to 4.1 mg/dL). All trials found similar baseline values for the treatment and control groups. In agreement with previous findings, our analyses suggest that the treatment effect was the largest in the trial with the lowest baseline serum creatinine (<a href="./references#CD005162-bbs2-0007" title="SolankiP , ChawlaA , GargR , GuptaR , JainM , SarinSK . Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology2003;18:152‐6. [MEDLINE: PMID: 12542598] ">Solanki 2003</a>). This may suggest that treatment should be administered early and that a protracted deterioration in renal function impedes recovery. Inclusion of non‐randomised, observational studies would have increased our ability to detect rare adverse events. However, we found no observational studies that reported adverse events to include in these analyses. </p> <p>A number of meta‐analyses have assessed the effect of terlipressin for hepatorenal syndrome (<a href="./references#CD005162-bbs2-0027" title="FabriziF , DixitV , MessaP , MartinP . Terlipressin for hepatorenal syndrome: a meta‐analysis of randomized trials. International Journal of Artificial Organs2009;32:133‐40. ">Fabrizi 2009</a>; <a href="./references#CD005162-bbs2-0026" title="DobreM , DemirjianS , SehgalAR , NavaneethanSD . Terlipressin in hepatorenal syndrome: a systematic review and meta‐analysis. International Urology and Nephrology2011;43(1):175‐84. ">Dobre 2010</a>; <a href="./references#CD005162-bbs2-0046" title="SagiSV , MittalS , KasturiKS , SoodGK . Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta‐analysis of randomized controlled trials. Journal of Gastroenterology and Hepatology2010;25:880‐5. ">Sagi 2010</a>). The results concerning mortality are equivocal. One meta‐analysis found that terlipressin increases survival among participants with type 1 hepatorenal syndrome (<a href="./references#CD005162-bbs2-0046" title="SagiSV , MittalS , KasturiKS , SoodGK . Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta‐analysis of randomized controlled trials. Journal of Gastroenterology and Hepatology2010;25:880‐5. ">Sagi 2010</a>). The two remaining meta‐analyses found no clear effect of terlipressin on survival, although only one performed a meta‐analysis addressing this question (<a href="./references#CD005162-bbs2-0027" title="FabriziF , DixitV , MessaP , MartinP . Terlipressin for hepatorenal syndrome: a meta‐analysis of randomized trials. International Journal of Artificial Organs2009;32:133‐40. ">Fabrizi 2009</a>). In agreement with our findings, all reviews found that terlipressin seems to improve renal function but also increases the risk of cardiovascular and ischaemic adverse events. The differences between the conclusions in the different reviews are mainly related to the inclusion criteria. For example, one review only included placebo‐controlled trials (<a href="./references#CD005162-bbs2-0027" title="FabriziF , DixitV , MessaP , MartinP . Terlipressin for hepatorenal syndrome: a meta‐analysis of randomized trials. International Journal of Artificial Organs2009;32:133‐40. ">Fabrizi 2009</a>). This decision is not clearly supported by previous evidence on the importance of bias control in RCTs (<a href="./references#CD005162-bbs2-0053" title="GluudLL , KjaerMS , ChristensenE . Terlipressin for hepatorenal syndrome. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD005162] ">Gluud 2006</a>; <a href="./references#CD005162-bbs2-0052" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanGD , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336:601‐5. ">Wood 2008</a>). Although lack of blinding may affect the risk of bias, there is no clear or consistent evidence to support the exclusion of open trials from meta‐analyses since the effect of blinding is inconsistent across trials. The extent, as well as the effect, of bias associated with lack of blinding is unpredictable and does not support the a priori exclusion of trials based on this component alone. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005162-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/urn:x-wiley:14651858:media:CD005162:CD005162-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_t/tCD005162-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD005162-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#CD005162-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005162-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/urn:x-wiley:14651858:media:CD005162:CD005162-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_t/tCD005162-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgments about each methodological quality item for each included study." data-id="CD005162-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgments about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#CD005162-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005162-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/urn:x-wiley:14651858:media:CD005162:CD005162-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_t/tCD005162-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005162-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#CD005162-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005162-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/urn:x-wiley:14651858:media:CD005162:CD005162-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_t/tCD005162-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of eight randomised clinical trials (525 participants) evaluating terlipressin versus placebo or no intervention for people with hepatorenal syndrome on mortality. Data from Hadengue 1998 is not included due to lack of events. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group risk (CGR) of mortality of 61.5%, and a model variance ‐based heterogeneity correction of 30%. The risk ratio is 0.85 (95% confidence interval 0.70 to 1.02). The cumulative Z‐curve (blue line) does not cross the diversity‐adjusted trial monitoring boundary for benefit." data-id="CD005162-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Trial Sequential Analysis of eight randomised clinical trials (525 participants) evaluating terlipressin versus placebo or no intervention for people with hepatorenal syndrome on mortality. Data from <a href="./references#CD005162-bbs2-0002" title="HadengueA , GadanoA , GiostraE , NegroF , MoreauR , VallaD , et al. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross‐over study. Hepatology (Baltimore, Md.)1995;22:165A. HadengueA , GadanoA , MoreauR , GiostraE , DurandF , VallaD , et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology1998;29:565‐70. [MEDLINE: PMID: 9824265] ">Hadengue 1998</a> is not included due to lack of events. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group risk (CGR) of mortality of 61.5%, and a model variance ‐based heterogeneity correction of 30%. The risk ratio is 0.85 (95% confidence interval 0.70 to 1.02). The cumulative Z‐curve (blue line) does not cross the diversity‐adjusted trial monitoring boundary for benefit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#CD005162-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005162-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/urn:x-wiley:14651858:media:CD005162:CD005162-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_t/tCD005162-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of seven randomised clinical trials (510 participants) evaluating terlipressin versus placebo/no intervention for people with hepatorenal syndrome on lack of reversal of hepatorenal syndrome. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group risk (CGR) of lack of reversal of hepatorenal syndrome of 88%, and a heterogeneity correction of 70%. The risk ratio is 0.64 (95% confidence interval 0.46 to 0.89). The cumulative Z‐curve (blue line) crosses the diversity‐adjusted trial monitoring boundary for benefit during the fourth trial." data-id="CD005162-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Trial Sequential Analysis of seven randomised clinical trials (510 participants) evaluating terlipressin versus placebo/no intervention for people with hepatorenal syndrome on lack of reversal of hepatorenal syndrome. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group risk (CGR) of lack of reversal of hepatorenal syndrome of 88%, and a heterogeneity correction of 70%. The risk ratio is 0.64 (95% confidence interval 0.46 to 0.89). The cumulative Z‐curve (blue line) crosses the diversity‐adjusted trial monitoring boundary for benefit during the fourth trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#CD005162-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005162-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/urn:x-wiley:14651858:media:CD005162:CD005162-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_t/tCD005162-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of four randomised clinical trials (234 participants) evaluating terlipressin versus placebo or no intervention for people with hepatorenal syndrome on cardiovascular adverse events. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group risk (CGR) of cardiovascular adverse events of 15%, and a heterogeneity correction of 20%. The risk ratio is 7.26 (95% confidence interval 1.70 to 31.05). The diversity‐adjusted trial monitoring boundary for harm is not included in the figure due to insufficient information. The estimated required information size is 4831 participants. Accordingly, with an accrued number of participants of 234, only 4.8% of the required number of participants has been achieved." data-id="CD005162-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Trial Sequential Analysis of four randomised clinical trials (234 participants) evaluating terlipressin versus placebo or no intervention for people with hepatorenal syndrome on cardiovascular adverse events. The analysis is made with power 90%, alpha 3%, a relative risk reduction (RRR) of 25%, a control group risk (CGR) of cardiovascular adverse events of 15%, and a heterogeneity correction of 20%. The risk ratio is 7.26 (95% confidence interval 1.70 to 31.05). The diversity‐adjusted trial monitoring boundary for harm is not included in the figure due to insufficient information. The estimated required information size is 4831 participants. Accordingly, with an accrued number of participants of 234, only 4.8% of the required number of participants has been achieved. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#CD005162-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005162-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/urn:x-wiley:14651858:media:CD005162:CD005162-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_t/tCD005162-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome 1 Mortality." data-id="CD005162-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome 1 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/references#CD005162-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005162-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/urn:x-wiley:14651858:media:CD005162:CD005162-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_t/tCD005162-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome 2 Mortality in randomised clinical trials evaluating terlipressin and albumin." data-id="CD005162-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome 2 Mortality in randomised clinical trials evaluating terlipressin and albumin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/references#CD005162-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005162-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/urn:x-wiley:14651858:media:CD005162:CD005162-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_t/tCD005162-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome 3 Hepatorenal syndrome." data-id="CD005162-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome 3 Hepatorenal syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/references#CD005162-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005162-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/urn:x-wiley:14651858:media:CD005162:CD005162-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_t/tCD005162-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome 4 Serious adverse events, total number." data-id="CD005162-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome 4 Serious adverse events, total number. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/references#CD005162-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005162-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/urn:x-wiley:14651858:media:CD005162:CD005162-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_t/tCD005162-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome 5 Serious adverse events, types." data-id="CD005162-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome 5 Serious adverse events, types. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/references#CD005162-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005162-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/urn:x-wiley:14651858:media:CD005162:CD005162-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_t/tCD005162-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome 6 Non‐serious adverse events." data-id="CD005162-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Terlipressin alone or with albumin versus no intervention or albumin, Outcome 6 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/references#CD005162-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/media/CDSR/CD005162/image_n/nCD005162-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005162-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Terlipressin versus placebo or no intervention for hepatorenal syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Terlipressin versus placebo or no intervention for hepatorenal syndrome. Administration of albumin allowed if administered to both the intervention and comparison group</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with hepatorenal syndrome<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> terlipressin alone or terlipressin plus albumin </p> <p><b>Comparison:</b> placebo or no intervention or albumin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with terlipressin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.85 (0.73 to 0.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>534<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Downgraded because of i) clinical heterogeneity and ii) the results of the Trial Sequential Analysis </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>688 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>536 per 1000<br/> (433 to 660) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>488 per 1000<br/> (394 to 600) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Hepatorenal syndrome</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.63 (0.48 to 0.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>510<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Downgraded because of i) clinical heterogeneity and ii) all trials are judged as 'high risk of bias'. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>879 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>510 per 1000<br/> (431 to 606) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>875 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>507 per 1000<br/> (429 to 604) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91 (0.68 to 1.21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>534 (9 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Downgraded because of i) clinical heterogeneity and ii) all RCTs are judged as high risk of bias. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>212 per 1000<br/> (131 to 344) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious cardiovascular adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 7.26 (1.70 to 31.05)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>234<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Downgraded because of i) clinical heterogeneity and ii) all RCTs are judged as high risk of bias </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Abdominal pain</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.54 (0.97 to 2.43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>294 (4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Downgraded because of i) clinical heterogeneity and ii) all RCTs are judged as high risk of bias </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>149 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>229 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diarrhoea</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.76 (2.19 to 15.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>240 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Downgraded because of i) clinical heterogeneity and ii) all RCTs are judged as high risk of bias </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Not confirmed in analyses of randomised clinical trials (RCTs) with a low risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Terlipressin versus placebo or no intervention for hepatorenal syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/full#CD005162-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005162-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Terlipressin alone or with albumin versus no intervention or albumin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.73, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Type 1 hepatorenal syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.63, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Type 1 or 2 hepatorenal syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.75, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality in randomised clinical trials evaluating terlipressin and albumin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.67, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hepatorenal syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.48, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Type 1 hepatorenal syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.47, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Type 2 hepatorenal syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.14, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Type 1 or 2 hepatorenal syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.46, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events, total number <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.68, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious adverse events, types <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Cardovascular adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.26 [1.70, 31.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Circulatory overload</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.59, 5.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Gastrointestinal bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.22, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Hepatic encephalopathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.68, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Respiratory distress/acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [0.84, 4.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Bacterial inflections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.39, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Total number</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.58, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.97, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Chest pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.25, 99.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Livedo reticularis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.12, 72.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.76 [2.19, 15.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Terlipressin alone or with albumin versus no intervention or albumin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005162.pub4/references#CD005162-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005162.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005162-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005162-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005162-note-0001">Français</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005162-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005162\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005162\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005162\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005162\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005162\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=SVRJ5zHF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005162.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005162.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005162.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005162.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005162.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729783378"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005162.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729783382"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005162.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ee54f7ca5f4d2',t:'MTc0MDcyOTc4My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 